×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RIGL – rigel pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RIGL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/9
12:17 am
rigl
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade) [Seeking Alpha]
Low
Report
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade) [Seeking Alpha]
4/7
08:05 am
rigl
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
3/31
08:39 am
rigl
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology [Yahoo! Finance]
Medium
Report
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology [Yahoo! Finance]
3/31
08:05 am
rigl
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Medium
Report
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
3/27
02:22 pm
rigl
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It's Doing Better Than People Realize” [Yahoo! Finance]
Low
Report
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It's Doing Better Than People Realize” [Yahoo! Finance]
3/10
06:55 am
rigl
Rigel Pharmaceuticals: Growing Where It Matters [Seeking Alpha]
Low
Report
Rigel Pharmaceuticals: Growing Where It Matters [Seeking Alpha]
3/4
12:02 pm
rigl
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress [Yahoo! Finance]
Low
Report
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress [Yahoo! Finance]
3/4
12:15 am
rigl
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and ... [Yahoo! Finance]
High
Report
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and ... [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
3/3/2026
04:01 pm
RIGL
rigel pharmaceuticals, inc.
BEAT
Report
-11.5%
rigel pharmaceuticals, inc.
11/4/2025
04:01 pm
RIGL
rigel pharmaceuticals, inc.
BEAT
Report
33.4%
rigel pharmaceuticals, inc.
8/5/2025
04:01 pm
RIGL
rigel pharmaceuticals, inc.
BEAT
Report
23.0%
rigel pharmaceuticals, inc.
5/6/2025
04:01 pm
RIGL
rigel pharmaceuticals, inc.
BEAT
Report
1.2%
rigel pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
04:03 pm
rigl
Form DEFA14A RIGEL PHARMACEUTICALS
Low
Report
Form DEFA14A RIGEL PHARMACEUTICALS
4/3
04:02 pm
rigl
Form DEF 14A RIGEL PHARMACEUTICALS For: May 14
Low
Report
Form DEF 14A RIGEL PHARMACEUTICALS For: May 14
3/27
11:38 am
rigl
Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: VANGUARD GROUP INC
3/3
04:14 pm
rigl
Form 8-K RIGEL PHARMACEUTICALS For: Mar 03
High
Report
Form 8-K RIGEL PHARMACEUTICALS For: Mar 03
3/3
04:09 pm
rigl
Form 10-K RIGEL PHARMACEUTICALS For: Dec 31
Medium
Report
Form 10-K RIGEL PHARMACEUTICALS For: Dec 31
2/24
04:58 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Feb 20 Filed by: MOOS WALTER H
Low
Report
Form 4 RIGEL PHARMACEUTICALS For: Feb 20 Filed by: MOOS WALTER H
2/20
01:52 pm
rigl
Form 144 RIGEL PHARMACEUTICALS Filed by: MOOS WALTER H
Low
Report
Form 144 RIGEL PHARMACEUTICALS Filed by: MOOS WALTER H
2/19
05:06 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Feb 17 Filed by: Rojkjaer Lisa
Medium
Report
Form 4 RIGEL PHARMACEUTICALS For: Feb 17 Filed by: Rojkjaer Lisa
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/13
Form 8-K RIGEL PHARMACEUTICALS For: Jan 13
20.0%
10/23 Here's Why Rigel Pharmaceuticals Stock Jumped as Much as 10.7% Today [The Motley Fool] 17.1%
4/27 Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update 9.0%
2/27 Rigel Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] 6.5%
6/28 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 6.5%
3/4 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.4%
5/23 Form 4 RIGEL PHARMACEUTICALS For: May 22 Filed by: Schorno Dean L 5.9%
5/21 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.9%
9/23 Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia 5.1%
8/6 Q2/2019 6/30/2019 EPS -0.120 ZacksConsensus -0.140 ActVsEst 0.020 - Beat 4.6%
10/23 Here's Why Rigel Pharmaceuticals Stock Jumped as Much as 10.7% Today [The Motley Fool] 17.1%
4/27 Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update 9.0%
2/27 Rigel Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] 6.5%
6/28 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 6.5%
3/4 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.4%
5/23 Form 4 RIGEL PHARMACEUTICALS For: May 22 Filed by: Schorno Dean L 5.9%
5/21 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.9%
9/23 Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia 5.1%
8/6 Q2/2019 6/30/2019 EPS -0.120 ZacksConsensus -0.140 ActVsEst 0.020 - Beat 4.6%
TOP News Decliners
4/1
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock.
-11.9%
11/6 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -9.9%
5/7 Form 8-K RIGEL PHARMACEUTICALS For: May 07 -7.4%
12/17 Rigel Announces Chief Commercial Officer Transition -6.4%
8/10 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.50 price target on the stock. -6.4%
4/30 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.8%
10/29 Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results -5.7%
5/1 Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders -5.5%
10/18 Rigel Pharma not quite there with European application for fostamatinib [Seeking Alpha] -4.9%
9/26 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $7.00 price target on the stock. -4.8%
11/6 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -9.9%
5/7 Form 8-K RIGEL PHARMACEUTICALS For: May 07 -7.4%
12/17 Rigel Announces Chief Commercial Officer Transition -6.4%
8/10 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.50 price target on the stock. -6.4%
4/30 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.8%
10/29 Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results -5.7%
5/1 Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders -5.5%
10/18 Rigel Pharma not quite there with European application for fostamatinib [Seeking Alpha] -4.9%
9/26 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $7.00 price target on the stock. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: